Press Releases :: Kazia Therapeutics (KZIA)

Sep 22, 2020 10:00 am EDT Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

Aug 24, 2020 5:30 am EDT US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

Aug 23, 2020 9:03 pm EDT US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

Aug 20, 2020 10:30 am EDT US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

Aug 7, 2020 10:30 am EDT US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

Jun 22, 2020 10:30 am EDT Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

Jun 1, 2020 10:30 am EDT Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

Apr 7, 2020 8:00 am EDT Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study